Koch Institute

Subterms

    More stories

    • 50 Shares199 Views

      in Security

      How diet affects tumors

      by

      In recent years, there has been some evidence that dietary interventions can help to slow the growth of tumors. A new study from MIT, which analyzed two different diets in mice, reveals how those diets affect cancer cells, and offers an explanation for why restricting calories may slow tumor growth.

      The study examined the effects of a calorically restricted diet and a ketogenic diet in mice with pancreatic tumors. While both of these diets reduce the amount of sugar available to tumors, the researchers found that only the calorically restricted diet reduced the availability of fatty acids, and this was linked to a slowdown in tumor growth.

      The findings do not suggest that cancer patients should try to follow either of these diets, the researchers say. Instead, they believe the findings warrant further study to determine how dietary interventions might be combined with existing or emerging drugs to help patients with cancer.

      “There’s a lot of evidence that diet can affect how fast your cancer progresses, but this is not a cure,” says Matthew Vander Heiden, director of MIT’s Koch Institute for Integrative Cancer Research and the senior author of the study. “While the findings are provocative, further study is needed, and individual patients should talk to their doctor about the right dietary interventions for their cancer.”

      MIT postdoc Evan Lien is the lead author of the paper, which appears today in Nature.

      Metabolic mechanism

      Vander Heiden, who is also a medical oncologist at Dana-Farber Cancer Institute, says his patients often ask him about the potential benefits of various diets, but there is not enough scientific evidence available to offer any definitive advice. Many of the dietary questions that patients have focus on either a calorie-restricted diet, which reduces calorie consumption by 25 to 50 percent, or a ketogenic diet, which is low in carbohydrates and high in fat and protein.

      Previous studies have suggested that a calorically restricted diet might slow tumor growth in some contexts, and such a diet has been shown to extend lifespan in mice and many other animal species. A smaller number of studies exploring the effects of a ketogenic diet on cancer have produced inconclusive results.

      “A lot of the advice or cultural fads that are out there aren’t necessarily always based on very good science,” Lien says. “It seemed like there was an opportunity, especially with our understanding of cancer metabolism having evolved so much over the past 10 years or so, that we could take some of the biochemical principles that we’ve learned and apply those concepts to understanding this complex question.”

      Cancer cells consume a great deal of glucose, so some scientists had hypothesized that either the ketogenic diet or calorie restriction might slow tumor growth by reducing the amount of glucose available. However, the MIT team’s initial experiments in mice with pancreatic tumors showed that calorie restriction has a much greater effect on tumor growth than the ketogenic diet, so the researchers suspected that glucose levels were not playing a major role in the slowdown.

      To dig deeper into the mechanism, the researchers analyzed tumor growth and nutrient concentration in mice with pancreatic tumors, which were fed either a normal, ketogenic, or calorie-restricted diet. In both the ketogenic and calorie-restricted mice, glucose levels went down. In the calorie-restricted mice, lipid levels also went down, but in mice on the ketogenic diet, they went up.

      Lipid shortages impair tumor growth because cancer cells need lipids to construct their cell membranes. Normally, when lipids aren’t available in a tissue, cells can make their own. As part of this process, they need to maintain the right balance of saturated and unsaturated fatty acids, which requires an enzyme called stearoyl-CoA desaturase (SCD). This enzyme is responsible for converting saturated fatty acids into unsaturated fatty acids.

      Both calorie-restricted and ketogenic diets reduce SCD activity, but mice on the ketogenic diet had lipids available to them from their diet, so they didn’t need to use SCD. Mice on the calorie-restricted diet, however, couldn’t get fatty acids from their diet or produce their own. In these mice, tumor growth slowed significantly, compared to mice on the ketogenic diet.

      “Not only does caloric restriction starve tumors of lipids, it also impairs the process that allows them to adapt to it. That combination is really contributing to the inhibition of tumor growth,” Lien says.

      Dietary effects

      In addition to their mouse research, the researchers also looked at some human data. Working with Brian Wolpin, an oncologist at Dana-Farber Cancer Institute and an author of the paper, the team obtained data from a large cohort study that allowed them to analyze the relationship between dietary patterns and survival times in pancreatic cancer patients. From that study, the researchers found that the type of fat consumed appears to influence how patients on a low-sugar diet fare after a pancreatic cancer diagnosis, although the data are not complete enough to draw any conclusions about the effect of diet, the researchers say.

      Although this study showed that calorie restriction has beneficial effects in mice, the researchers say they do not recommend that cancer patients follow a calorie-restricted diet, which is difficult to maintain and can have harmful side effects. However, they believe that cancer cells’ dependence on the availability of unsaturated fatty acids could be exploited to develop drugs that might help slow tumor growth.

      One possible therapeutic strategy could be inhibition of the SCD enzyme, which would cut off tumor cells’ ability to produce unsaturated fatty acids.

      “The purpose of these studies isn’t necessarily to recommend a diet, but it’s to really understand the underlying biology,” Lien says. “They provide some sense of the mechanisms of how these diets work, and that can lead to rational ideas on how we might mimic those situations for cancer therapy.”

      The researchers now plan to study how diets with a variety of fat sources — including plant or animal-based fats with defined differences in saturated, monounsaturated, and polyunsaturated fatty acid content — alter tumor fatty acid metabolism and the ratio of unsaturated to saturated fatty acids.

      The research was funded by the Damon Runyon Cancer Research Foundation, the National Institutes of Health, the Lustgarten Foundation, the Dana-Farber Cancer Institute Hale Family Center for Pancreatic Cancer Research, Stand Up to Cancer, the Pancreatic Cancer Action Network, the Noble Effort Fund, the Wexler Family Fund, Promises for Purple, the Bob Parsons Fund, the Emerald Foundation, the Howard Hughes Medical Institute, the MIT Center for Precision Cancer Medicine, and the Ludwig Center at MIT. More

    • 125 Shares99 Views

      in Energy

      Institute Professor Paula Hammond named to White House science council

      by

      Paula Hammond, an MIT Institute Professor and head of MIT’s Department of Chemical Engineering, has been chosen to serve on the President’s Council of Advisors on Science and Technology (PCAST), the White House announced today.

      The council advises the president on matters involving science, technology, education, and innovation policy. It also provides the White House with scientific and technical information that is needed to inform public policy relating to the U.S. economy, U.S. workers, and national security.

      “For me, this is an exciting opportunity,” Hammond says. “I have always been interested in considering how science can solve important problems in our community, in our country, and globally. It’s very meaningful for me to have a chance to have an advisory role at that level.”

      Hammond is one of 30 members named to the council, which is co-chaired by Frances Arnold, a professor at Caltech, and Maria Zuber, MIT’s vice president for research.

      “Paula is an extraordinary engineer, teacher, and colleague, and President Biden’s decision to appoint her to the council is an excellent one,” Zuber says. “I think about the work ahead of us — not just to restore science and technology to their proper place in policymaking, but also to make sure that they lead to real improvements in the lives of everyone in our country — and I can’t think of anyone better suited to the challenge than Paula.”

      Hammond, whose research as a chemical engineer touches on the fields of both medicine and energy, said she hopes to help address critical issues such as equal access to health care and efforts to mitigate climate change.

      “I’m very excited about the opportunities presented at the interface of engineering and health, and in particular, how we might be able to expand the benefits that we gain from our work to a broader set of communities, so that we’re able to address some of the disparities we see in health, which have been so obvious during the pandemic,” says Hammond, who is also a member of MIT’s Koch Institute for Integrative Cancer Research. “How we might be able to use everything from computational modeling and data science to technological innovation to equalize access to health is one area that I care a lot about.”

      Hammond’s research focuses on developing novel polymers and nanomaterials for a variety of applications in drug delivery, noninvasive imaging, solar cells, and battery technology. Using techniques for building polymers with highly controlled architectures, she has designed drug-delivering nanoparticles that can home in on tumors, as well as polymer films that dramatically improve the efficiency of methanol fuel cells.

      As an MIT faculty member and mentor to graduate students, Hammond has worked to increase opportunities for underrepresented minorities in science and engineering fields. That is a goal she also hopes to pursue in her new role.

      “There’s a lot of work to be done when we look at the low numbers of students of color who are actually going on to science and engineering fields,” she says. “When I think about my work related to increasing diversity in those areas, part of the reason I do it is because that’s where we gain excellence, and where we gain solutions and the foresight to work on the right problems. I also think that it’s important for there to be broad access to the power that science brings.”

      Hammond, who earned both her bachelor’s degree and PhD from MIT, has been a member of the faculty since 1995. She has been a full professor since 2006 and has chaired the Department of Chemical Engineering since 2015. Earlier this year, she was named an Institute Professor, MIT’s highest faculty honor. She is also one of only 25 people who have been elected to all three National Academies — Engineering, Science, and Medicine.

      She has previously served on the U.S. Secretary of Energy Scientific Advisory Board, the NIH Center for Scientific Review Advisory Council, and the Board of Directors of the American Institute of Chemical Engineers. She also chaired or co-chaired two committees that contributed landmark reports on gender and race at MIT: the Initiative for Faculty Race and Diversity, and the Academic and Organizational Relationships Working Group. More